E-mail: petrucci@bce.uniroma1.it
Odborné práce publikované na Linkos.cz
Přehled odborných textů publikovaných autorem na portálu Linkos.cz. Jsou zde uvedeny knihy a brožury, články v Klinické onkologii, tuzemská abstrakta z databáze abstrakt a další texty. Rejstřík není v žádném případě úplným autorským rejstříkem, protože jsou zde uvedeny pouze texty zveřejněné na portálu Linkos.cz.
Publikovaná abstrakta
- A Phase 3 Study Evaluating the Efficacy and Safety of Lenalidomide Combined with Melphalan and Prednisone In Patients ≥ 65 Years with Newly Diagnosed Multiple Myeloma (NDMM): Continuous Use of Lenalidomide Vs Fixed-Duration Regimens
- A Phase III Study Of ASCT Vs Cyclophosphamide-Lenalidomide-Dexamethasone and Lenalidomide-Prednisone Maintenance Vs Lenalidomide Alone In Newly Diagnosed Myeloma Patients
- Autologous Transplantation Versus Cyclophosphamide-Lenalidomide-Prednisone Followed By Lenalidomide-Prednisone Versus Lenalidomide Maintenance in Multiple Myeloma: Long-Term Results of a Phase III Trial
- Bortezomib Plus Melphalan–Prednisone Continues to Demonstrate a Survival Benefit Vs Melphalan–Prednisone in the Phase III VISTA Trial in Previously Untreated Multiple Myeloma After 3 Years Follow-up and Extensive Subsequent Therapy Use
- Carfilzomib (K) vs low-dose corticosteroids and optional cyclophosphamide (Cy) in patients (pts) with relapsed and refractory multiple myeloma (RRMM): Results from a phase 3 study (FOCUS)
- Continued Overall Survival Benefit After 5 Years’ Follow-up with Bortezomib-Melphalan-Prednisone (VMP) Versus Melphalan-Prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and No Increased Risk of Second Primary Malignancies...
- CONTINUOUS LENALIDOMIDE TREATMENT FOR TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: UPDATE ON PATIENTS AGED 65-75 YEARS ENROLLED IN MM-015
- EARLY AUTOLOGOUS STEM CELL TRANSPLANTATION IMPROVES SURVIVAL IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
- EARLY MORTALITY IN ELDERLY NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH NOVEL AGENTS: A POOLED ANALYSIS OF TWO LARGE RANDOMIZED PHASE III TRIALS
- GERIATRIC ASSESSMENT PREDICTS SURVIVAL AND RISK OF SERIOUS ADVERSE EVENTS FOR ELDERLY NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
- Impact of Complete Response on Survival with Either Autologous Stem Cell Transplantation or Conventional Chemotherapy: Results of a Pooled Analysis of 5 Phase III Trials in Newly Diagnosed Multiple Myeloma Patients
- IMPACT OF CONTINUOUS TREATMENT VS FIXED DURATION OF THERAPY IN NEWLY DIAGNOSED MYELOMA PATIENTS: PFS1, PFS2, OS ENDPOINTS
- IMPACT OF RENAL IMPAIRMENT ON THE EFFICACY AND SAFETY OF MELPHALAN-PREDNISONE-LENALIDOMIDE (LEN) INDUCTION FOLLOWED BY LEN MAINTENANCE IN NEWLY DIAGNOSED MULTIPLE MYELOMA: MM-015 POST-HOC ANALYSIS
- IMPROVED OVERALL SURVIVAL WITH AUTOLOGOUS TRANSPLANTATION VS CYCLOPHOSPHAMIDE-LENALIDOMIDE-DEXAMETHASONE IN NEWLY DIAGNOSED MYELOMA: A PHASE 3 TRIAL
- Incidence of second primary malignancy (SPM) in melphalan-prednisone-lenalidomide combination followed by lenalidomide maintenance (MPR-R) in newly diagnosed multiple myeloma patients (pts) age 65 or older
- Lenalidomide (LEN)-melphalan-prednisone induction followed by LEN maintenance (MPR-R) in newly diagnosed multiple myeloma (NDMM) elderly patients (Pts) with moderate renal impairment (RI): MM-015 trial post-hoc analysis.
- LENALIDOMIDE PLUS MELPHALAN AND PREDNISONE FOLLOWED BY LENALIDOMIDE MAINTENANCE PROVIDES FAVOURABLE EFFICACY AND HEALTH-RELATED QUALITY-OF-LIFE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS ≥65 YEARS
- Melphalan, Prednisone and Lenalidomide Followed by Lenalidomide Maintenance Displays Treatment Characteristics Favourable to Global Quality of Life in Newly Diagnosed Multiple Myeloma (NDMM) Patients ≥ 65 Years
- Melphalan, Prednisone and Lenalidomide Followed by Lenalidomide Maintenance Improves Health-Related Quality of Life (HRQoL), with Newly Diagnosed Multiple Myeloma (NDMM) Patients ≥ 65 Years Benefiting From Delays in Disease Progression
- MMY-3002: A Phase 3 Study Comparing BortezomibMelphalanPrednisone (VMP) with MelphalanPrednisone (MP) in Newly Diagnosed Multiple Myeloma.
- Significant Survival Improvement with Maintenance in Patients Achieving a Complete Response: Pooled Analysis of 4 Italian Phase III Trials in Newly Diagnosed Multiple Myeloma Patients
- The Combination of Frailty and ISS Scores Identifies a Simple Prognostic Index for Overall Survival in Elderly Patients Treated with Novel Agents-Based Induction Therapy
- Updated Follow-up and Results of Subsequent Therapy in the Phase III VISTA Trial: Bortezomib Plus Melphalan–Prednisone Versus Melphalan–Prednisone in Newly Diagnosed Multiple Myeloma
